Short Interest in Pluri Inc. (NASDAQ:PLUR) Decreases By 29.8%

Pluri Inc. (NASDAQ:PLUR) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 18,100 shares, a decrease of 29.8% from the February 28th total of 25,800 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average daily volume of 11,100 shares, the days-to-cover ratio is currently 1.6 days.

Pluri Trading Down 1.6 %

Shares of NASDAQ:PLUR traded down $0.07 during trading hours on Monday, hitting $4.32. 3,226 shares of the company’s stock traded hands, compared to its average volume of 17,274. Pluri has a 1 year low of $4.07 and a 1 year high of $6.60. The company has a debt-to-equity ratio of 4.44, a current ratio of 5.04 and a quick ratio of 5.04. The firm has a market capitalization of $30.23 million, a P/E ratio of -0.77 and a beta of 1.76. The business has a fifty day moving average price of $4.47 and a 200-day moving average price of $4.76.

Pluri (NASDAQ:PLUR) last released its earnings results on Tuesday, February 11th. The company reported ($0.53) earnings per share for the quarter. Pluri had a negative return on equity of 2,778.13% and a negative net margin of 3,551.49%.

Hedge Funds Weigh In On Pluri

A hedge fund recently raised its stake in Pluri stock. Renaissance Technologies LLC boosted its position in shares of Pluri Inc. (NASDAQ:PLUR) by 38.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,025 shares of the company’s stock after purchasing an additional 9,400 shares during the quarter. Renaissance Technologies LLC owned about 0.61% of Pluri worth $145,000 as of its most recent filing with the Securities & Exchange Commission. 16.59% of the stock is owned by institutional investors.

Pluri Company Profile

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.